马传染性贫血病毒Env假型报告病毒的开发与特性分析
Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.
作者信息
Tallmadge R L, Brindley M A, Salmans J, Mealey R H, Maury W, Carpenter S
机构信息
Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99163, USA.
出版信息
Clin Vaccine Immunol. 2008 Jul;15(7):1138-40. doi: 10.1128/CVI.00088-08. Epub 2008 Apr 30.
Abstract
We developed a replication-defective reporter virus pseudotyped with the envelope glycoprotein of equine infectious anemia virus (EIAV). The in vitro host range and neutralization phenotype of EIAV Env-pseudotyped virus were similar to those of replication-competent virus. An EIAV Env pseudovirus will improve antigenic characterization of viral variants and evaluation of lentivirus vaccines.
摘要
我们构建了一种复制缺陷型报告病毒，其包膜糖蛋白为马传染性贫血病毒（EIAV）的包膜糖蛋白。EIAV包膜糖蛋白假型化病毒的体外宿主范围和中和表型与具有复制能力的病毒相似。EIAV包膜假病毒将改善病毒变异体的抗原特性鉴定以及慢病毒疫苗的评估。
相似文献
1
Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.
Clin Vaccine Immunol. 2008 Jul;15(7):1138-40. doi: 10.1128/CVI.00088-08. Epub 2008 Apr 30.
2
Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus.
Virology. 1999 Sep 30;262(2):416-30. doi: 10.1006/viro.1999.9939.
3
Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus.
J Gen Virol. 2007 Apr;88(Pt 4):1324-1336. doi: 10.1099/vir.0.82391-0.
4
In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus.
Virology. 1999 Jul 5;259(2):416-27. doi: 10.1006/viro.1999.9772.
5
Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies.
J Gen Virol. 1996 Mar;77 ( Pt 3):435-42. doi: 10.1099/0022-1317-77-3-435.
6
Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors.
J Virol. 1999 Apr;73(4):2762-9. doi: 10.1128/JVI.73.4.2762-2769.1999.
7
Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.
J Virol. 2008 Apr;82(8):4052-63. doi: 10.1128/JVI.02028-07. Epub 2008 Jan 30.
8
Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies.
J Virol. 1987 Oct;61(10):2956-61. doi: 10.1128/JVI.61.10.2956-2961.1987.
9
Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection.
Arch Virol. 1990;111(3-4):199-212. doi: 10.1007/BF01311054.
10
Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.
J Virol. 2002 Nov;76(21):10588-97. doi: 10.1128/jvi.76.21.10588-10597.2002.
引用本文的文献
1
S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13197-13202. doi: 10.1073/pnas.1612044113. Epub 2016 Nov 1.
2
Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity.
Int J Nanomedicine. 2014 Dec 30;10:229-43. doi: 10.2147/IJN.S72264. eCollection 2015.
3
High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors.
J Gene Med. 2013 Jan;15(1):51-62. doi: 10.1002/jgm.2695.
4
Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.
J Virol. 2011 Oct;85(19):10421-4. doi: 10.1128/JVI.05349-11. Epub 2011 Jul 13.
5
Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.
J Virol. 2011 Jul;85(13):6814-8. doi: 10.1128/JVI.00077-11. Epub 2011 May 4.
6
An equine infectious anemia virus variant superinfects cells through novel receptor interactions.
J Virol. 2008 Oct;82(19):9425-32. doi: 10.1128/JVI.01142-08. Epub 2008 Jul 30.
本文引用的文献
1
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus.
J Virol. 2008 Jan;82(2):966-73. doi: 10.1128/JVI.01872-07. Epub 2007 Oct 31.
2
Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease.
Virology. 2007 Jun 20;363(1):156-65. doi: 10.1016/j.virol.2007.01.037. Epub 2007 Feb 27.
3
Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus.
Am J Trop Med Hyg. 2006 Oct;75(4):702-9.
4
Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
Virology. 2006 Mar 30;347(1):36-51. doi: 10.1016/j.virol.2005.11.019. Epub 2005 Dec 27.
5
Altering the tropism of lentiviral vectors through pseudotyping.
Curr Gene Ther. 2005 Aug;5(4):387-98. doi: 10.2174/1566523054546224.
6
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
J Virol. 2005 Aug;79(16):10108-25. doi: 10.1128/JVI.79.16.10108-10125.2005.
7
Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
J Virol. 2005 Jan;79(2):1252-61. doi: 10.1128/JVI.79.2.1252-1261.2005.
8
The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8. doi: 10.1089/aid.2004.20.1254.
9
Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.
J Infect Dis. 2004 Sep 15;190(6):1119-26. doi: 10.1086/423286. Epub 2004 Aug 2.
10
Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony.
Virology. 2001 Jan 5;279(1):185-200. doi: 10.1006/viro.2000.0696.
Zotero 插件